William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on October 20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Phipps has given his Buy rating due to a combination of factors including the promising results from Upstream Bio’s recent Phase II VIBRANT trial. The trial showcased the potential of their TSLP-receptor antibody, verekitug, in treating patients with CRSwNP, which has sparked increased investor interest. The upcoming Phase II VALOUR trial in asthma patients is anticipated to further validate the efficacy of verekitug, with management setting a 50% exacerbation reduction as the benchmark for success.
Furthermore, the management’s strategic outlook and the potential for verekitug to match or exceed the efficacy of existing treatments like Tezspire, but with more convenient dosing intervals, add to the stock’s appeal. The insights from the investor meetings reinforce confidence in Upstream Bio’s ability to deliver on its value proposition, making it a compelling investment opportunity according to Phipps.
In another report released on October 20, Piper Sandler also maintained a Buy rating on the stock with a $75.00 price target.